Aspirin was introduced into clinical medicine in 1899 and its anti-inflammatory, analgesic and antipyretic properties were accompanied by the onset of gastrointestinal and renal toxicity. Over the ...

A drug developer's dream, rationally designed to quell inflammation, COX-2 inhibitors are also prime candidates for preventing cancer or its recurrence. Gary J. Kelloff, chief of the chemoprevention ...

Cyclooxygenase-2 (COX-2) inhibitors have long been employed to modulate inflammatory responses in a range of conditions, from arthritis to malignancies. In recent years, the convergence of ...

Taking the oral cyclo-oxygenase (COX)-2 inhibitor piroxicam in combination with levonorgestrel improved emergency contraception efficacy versus levonorgestrel alone, with no additional adverse events, ...

This issue of examines interventions aimed at improvingdrug safety. 1-4 The need for a rigorous researchagenda in pharmaceutical safety is highlighted byMerck's ...

AAT-076 was tested in the preclinical setting for its analgesic potential in COX-1 and COX-2 assays, as well as in in vivo rat models of air pouch inflammation, adjuvant-induced arthritis and ...

PHILADELPHIA-- Nimesulide, a cyclooxygenase-2 (COX-2) inhibitor, delays the progression of precancerous pancreatic lesions in mice, according to researchers at David Geffen School of Medicine at UCLA.

Boston, MA (October 15, 2002) – The use of a selective COX (cyclooxygenase)-2 inhibitor (celecoxib) significantly reduced the incidence of breast cancer in HER-2/neu overexpressing mice, according to ...

SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic ...

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or ...

BAE: Bovine aortic endothelial; RHP: Recombinant human protein. NSAIDs variably inhibit prostaglandin H synthase (COX). COX-2 was cloned in 1991, and it was subsequently established that COX-1 does ...